A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Active, not recruiting
Eli Lilly and Company
Phase 2
The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or
merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or
metastatic biliary tract cancer.
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
Completed
Eli Lilly and Company
Phase 1
The main purpose of this study is to evaluate the safety of ramucirumab in combination with
other targeted agents in participants with advanced cancers.
A Study of Merestinib (LY2801653) in Healthy Participants
Completed
Eli Lilly and Company
Phase 1
The purpose of this study is to evaluate the effect of food on merestinib (standard meal and
high-fat meal) compared to the fasted state. The study will also measure how much of the
study drug gets into the blood stream and how long it takes the body to get rid of it. In
addition, the tolerability of the study drug will be evaluated. Information about any side
effects that may occur will also be collected. The study will last approximately 28 days.
Screening is required within 28 days prior to the start of the study.
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
Active, not recruiting
Eli Lilly and Company
Phase 1
The main purpose of this study is to evaluate the safety and tolerability of anti-programmed
cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced
refractory solid tumors.
Merestinib In Non-Small Cell Lung Cancer And Solid Tumors
Active, not recruiting
Eli Lilly and Company
Phase 2
This research study is examining merestinib (a targeted therapy) as a possible treatment for
non-small cell lung cancer (NSCLC) that was found to have a specific change in the MET gene
(a MET exon 14 mutation); or as a treatment for solid tumors that have an alteration in the
NTRK gene (an NTRK1, 2, or 3 rearrangement).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
